News
OCS
18.05
+0.89%
0.16
Weekly Report: what happened at OCS last week (0414-0418)?
Weekly Report · 4d ago
Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga · 04/17 12:49
Oculis Holding Price Target Maintained With a $28.00/Share by Chardan Capital
Dow Jones · 04/17 11:45
Oculis Holding Is Maintained at Buy by Chardan Capital
Dow Jones · 04/17 11:45
Chardan Capital Maintains Buy on Oculis Holding, Maintains $28 Price Target
Benzinga · 04/17 11:34
Oculis Holding Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/17 10:55
Oculis Holding Price Target Raised to $32.00/Share From $29.00 by HC Wainwright & Co.
Dow Jones · 04/17 10:55
HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $32
Benzinga · 04/17 10:45
Oculis price target raised to $32 from $29 at H.C. Wainwright
TipRanks · 04/17 10:05
Oculis Holding’s Promising Future: Advancements in Neuroprotection, Dry Eye Treatment, and Diabetic Macular Edema
TipRanks · 04/17 06:35
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award
Barchart · 04/17 04:00
Oculis Holding (OCS) Receives a Buy from Bank of America Securities
TipRanks · 04/16 10:18
Oculis Holding AG Unveils Key Clinical Updates and Future Outlook at R&D Day
TipRanks · 04/15 20:27
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets
Barchart · 04/15 03:00
Weekly Report: what happened at OCS last week (0407-0411)?
Weekly Report · 04/14 09:51
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
Barchart · 04/10 03:00
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Barchart · 04/09 16:00
Weekly Report: what happened at OCS last week (0331-0404)?
Weekly Report · 04/07 09:50
A First Look At Oculis Holding AG: Revenues Still Several Years Away
Seeking Alpha · 04/03 16:25
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
Barchart · 04/01 03:00
More
Webull provides a variety of real-time OCS stock news. You can receive the latest news about Oculis Holding through multiple platforms. This information may help you make smarter investment decisions.
About OCS
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.